SCHEMBL4019355

SCHEMBL4019355

Cc1c2c(=O)n(CC(F)CNC(=O)OC(C)(C)C)c3cc4c(cc3c2nn1Cc1ccccc1)CCCC4

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.35
CYP2D6 P10635 3/20 0.34
BRD4 O60885 1/20 0.33
HTR2C P28335 1/20 0.33
SLC6A4 P31645 1/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
TSHR P16473 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CYP1A2 P05177 2/20 0.33
GNRHR P30968 1/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
SYK P43405 1/20 0.33
EEF2K O00418 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5128333 0.91 PTGDR2 (0.35) PTGDR2CYP2D6BRD4HTR2CSLC6A4
SCHEMBL4023100 0.86 CHEK1 (0.33) RAB9ALMNAMAPTTSHRKDM4E
SCHEMBL4014749 0.86 CHEK1 (0.33) RAB9ALMNAMAPTTSHRKDM4E
SCHEMBL4017813 0.86 CHEK1 (0.33) RAB9ALMNAMAPTTSHRKDM4E
SCHEMBL5129516 0.86 CNR2 (0.41) PTGDR2CYP2D6BRD4GNRHRKMT2A
SCHEMBL4017815 0.80 CHEK1 (0.50) RAB9ALMNAMAPTKDM4E
SCHEMBL14192084 0.74 PRMT5 (0.34) PTGDR2MAPTPDE5APOLBKMT2A
SCHEMBL5128346 0.74 CHEK1 (0.41) PTGDR2SMN1; SMN2PDE4APDE4BPDE4C
SCHEMBL5132632 0.70 CHEK1 (0.46) CYP2D6LMNASMN1; SMN2CYP1A2KMT2A
SCHEMBL4018879 0.65 CHEK1 (0.51) PTGDR2HTR2CLMNAMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7550477-B2 Inhibitors of checkpoint kinases MERCK & CO., INC. (US) 2009-06-23 US disclosed
US-7550477-B2 Inhibitors of checkpoint kinases MERCK & CO., INC. (US) 2009-06-23 US disclosed
US-20090023767-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-01-22 US disclosed
US-20090023767-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023767-A1 Inhibitors of Checkpoint Kinases CHEK1, CHEK2, BUB1B PTGDR2 4316/4885CYP2D6 4516/4885BRD4 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.